Melatonin sits in medicine cabinets across the country primarily as a sleep aid – a low-cost tablet most people take thirty minutes before bed when they can’t shut their brains off. That reputation is accurate but incomplete. A large review of clinical trial data published in June 2026 found that melatonin produced pain reductions numerically comparable to some of the most widely prescribed analgesics on the market. The supplement people are already taking for sleep may, in many cases, also be quietly doing something for their pain.
The review, published in PAIN – the official journal of the International Association for the Study of Pain – pooled data from 23 randomized controlled trials (RCTs) involving 2,028 participants, with the stated aim of evaluating melatonin’s efficacy on both pain intensity and sleep quality across musculoskeletal conditions.
Those trials spanned multiple countries, including the United States, Russia, Brazil, Egypt, and China, and covered a wide spectrum of conditions: low back pain, osteoarthritis, fibromyalgia, and recovery from surgeries including joint replacements and spinal procedures. Taken together, it represents the most comprehensive body of evidence yet assembled on melatonin as a sleep supplement for chronic pain.
Executive Summary
On average, the analysis found that melatonin reduced pain by around nine points on a 0 – 100 scale, with the most rigorous trials showing reductions closer to 10 points – a magnitude described as similar to widely used pain medications. The supplement also improved sleep quality across the populations studied, reinforcing the well-established link between pain and sleep. Researchers from the University of Sydney who led the study were careful to note important limitations: the certainty of evidence was rated low to moderate, no single optimal dose emerged from the data, and the findings do not position melatonin as a direct replacement for existing pain therapies. What the evidence does suggest is that a supplement already present in millions of homes may be carrying a secondary biological function that medicine has only recently begun to take seriously.
The Scale of the Problem Melatonin Could Help Address
Musculoskeletal pain – encompassing conditions that affect the muscles, bones, joints, tendons, and ligaments – affects up to 47 percent of people globally, with participants in the analyzed trials presenting with conditions including low back pain, osteoarthritis, and fibromyalgia, as well as post-surgical pain.
According to a 2025 analysis of the Global Burden of Disease Study 2021, musculoskeletal disorders – including lower back pain, neck pain, osteoarthritis, and rheumatoid arthritis – represent a leading global cause of disability, affecting over 1.69 billion individuals. The burden is not static. Significant increases in musculoskeletal disorder prevalence have occurred globally, including more than a 95% growth in total cases since 1990, driven largely by aging populations.
The standard pharmacological response to severe musculoskeletal pain – particularly in the United States – has long centered on opioids, NSAIDs (non-steroidal anti-inflammatory drugs, such as ibuprofen), and acetaminophen (paracetamol). Each carries meaningful risks at scale. A long-term randomized trial of stepped therapy for chronic musculoskeletal pain found no difference in function – and actually higher pain intensity – when opioid therapy was the starting point compared to nonopioid approaches, according to the CDC’s 2022 clinical practice guideline for prescribing opioids. As a 2025 analysis published in Frontiers in Pain Research noted, opioid use carries substantial risks of dependence, misuse, and diversion, even over short periods.
Against that backdrop, the melatonin findings take on additional relevance. Lead researcher Kangchao Wu and co-author Professor Paulo Ferreira of the University of Sydney noted that melatonin “is already in people’s homes, it’s inexpensive, and we know it’s safe,” adding that the results open the door to reducing reliance on medications that carry greater risks.
What the 23-Trial Review Actually Found
To conduct the analysis, researchers systematically searched six major medical databases for every relevant study published through April 2025, restricting their inclusion to randomized controlled trials – the study design considered most reliable for isolating the effect of a specific treatment – where patients were randomly assigned and blinding was maintained.
Participants had to be dealing with pain lasting three months or longer, or pain arising from surgical recovery. Comparators included both placebo arms and active controls – meaning some trial participants were compared against established analgesics, not just a sugar pill. The review found that melatonin was tied to less pain and better sleep in people dealing with musculoskeletal conditions long-term, though the quality of evidence was rated low to moderate, and researchers noted that comparable numeric reductions do not automatically make melatonin a swap-in for existing pain medications.
The headline result – roughly nine points on a 100-point pain scale – requires context to interpret correctly. Researchers described the effect size as roughly comparable to that of common NSAIDs like ibuprofen, which is a notable finding for a supplement with melatonin’s safety profile. The key caveat is that the evidence base, while the largest assembled to date on this question, remains limited in certainty. The trials varied in design, population, duration, and dosing, which is why the authors stopped well short of clinical recommendations.
Chronic Pain vs. Postoperative Pain: A Critical Distinction
An earlier 2020 meta-analysis found that melatonin reduced chronic pain across the studies examined, while concluding there was insufficient evidence for acute postoperative or procedural pain in rigorous high-quality trials. The 2026 review adds considerably more trial data to this picture. Across the 23 randomized trials, melatonin supplementation produced modest reductions in both chronic musculoskeletal and postoperative pain – roughly 9 to 10 points on a 100-point scale – with adverse events similar to placebo and no serious events reported. The two categories of pain – chronic and postoperative – are biologically distinct, and the researchers analyzed them separately. Results were more consistent for chronic conditions than for post-surgical recovery, where variability between individual trials was higher.
Sleep Quality as a Secondary Finding
Beyond pain intensity, melatonin improved sleep quality across the conditions studied, which the authors described as reinforcing the well-established relationship between pain and sleep disturbance. This is not a trivial secondary finding. Pain and sleep exist in a documented bidirectional relationship: poor sleep amplifies pain sensitivity, and persistent pain disrupts sleep architecture. A supplement that addresses both simultaneously – even modestly – has a compounding practical value that single-symptom analyses tend to undercount.
For people already taking melatonin as a sleep supplement for chronic pain management, the implication is that they may have been receiving an additional analgesic benefit without knowing it. For clinicians, it raises a question worth evaluating: for patients who both experience chronic musculoskeletal pain and struggle with sleep, melatonin may offer dual utility that warrants more deliberate consideration.
Why Melatonin May Affect Pain: The Biological Mechanisms
Melatonin is a hormone naturally synthesized and secreted primarily by the pineal gland – a small structure in the brain – and its core function is regulating the body’s circadian rhythm (its internal 24-hour clock), including the sleep-wake cycle. Its antinociceptive (pain-reducing) properties, however, operate through a separate set of pathways that research has been mapping for over a decade.
Lead author Kangchao Wu told Healthline that “melatonin may have some intrinsic pain-relieving properties, such as antioxidant and anti-inflammatory effects, which are very crucial effects during the pain process.”
Research has demonstrated that melatonin exerts antinociceptive actions at both the spinal cord and the brain itself, and that its mechanisms involve multiple receptor systems, including opioid, serotonergic, and cholinergic receptors. Most notably, the involvement of MT1 and MT2 melatonin receptors in the spinal cord has been well-documented as an antinociceptive mechanism across multiple animal models of pain perception.
At the cellular level, melatonin activates G-protein-coupled Kir3 channels – ion channels that influence neuron firing – which reduce the rapid firing of action potentials in neurons. It also inhibits voltage-gated sodium channels, including Nav1.8 and Nav1.9, producing anti-thermal hypersensitivity and anti-mechanical allodynia effects (meaning it may reduce sensitivity to heat and touch-related pain signals).
Additional proposed mechanisms include indirect activation of opioid receptors, inhibition of proinflammatory cytokines (signaling proteins that drive inflammation), activation of GABA-A receptors (which have sedating and pain-modulating effects), and antioxidant activity. The convergence of these pathways means melatonin is not acting on pain through a single channel – it appears to engage several of the same systems that established analgesics target, which may help explain why its measured effects in clinical trials approach the range seen with those medications.
Dosing: What the Trials Used and What the Evidence Can Support
One of the study’s more practically important findings – and one of its more honest admissions – concerns dosing. Researchers did not find evidence of a clear dose-response relationship, meaning no single “best” dose can be recommended from the current evidence. This matters because it means the data cannot yet tell clinicians whether 3 mg works meaningfully better than 5 mg, or whether 10 mg provides additional benefit over either.
What the trials used as a practical matter, however, provides some guidance. For chronic musculoskeletal pain, doses in the reviewed trials typically ranged from 3 to 10 mg, with 3 mg per day the most commonly used dose. For postoperative pain, doses ranged from 1 to 10 mg, with 5 to 6 mg most common, generally taken at bedtime or up to one hour before sleep.
For general sleep use, research summarized by Drugs.com indicates that 0.5 mg to 5 mg is considered the optimal range for safe and effective dosing in adults, with no FDA-established maximum dose. The chronic pain trials were using doses at or above the higher end of that range, which may be relevant for anyone considering adding melatonin to their pain management routine.
The practical implication: if someone is already taking 3 mg of melatonin at bedtime for sleep, that dose aligns with the most commonly studied dose in the chronic pain literature. Starting there is defensible based on available evidence, but the absence of a dose-response relationship means dose adjustments should be guided by a physician, not self-experimented.
Safety Profile: What the Evidence Supports – and What Remains Unknown
The review’s safety data – drawn from 23 randomized controlled trials, including only studies in people with chronic or postoperative musculoskeletal pain – found that melatonin was generally well tolerated across doses ranging from 1 to 10 mg. The most commonly reported side effects were nausea, dizziness, and headaches, with overall rates similar to placebo and no serious adverse events reported.
The review further concluded that melatonin is generally considered safe for short-term use of less than three months, and noted that it is typically low cost – often less than $1.50 per tablet – and shows no evidence of dependence. Those characteristics distinguish it sharply from opioids and even long-term NSAID use, which carries risks of gastrointestinal damage, cardiovascular effects, and renal impairment.
However, the short-term safety finding carries an important boundary. Longer-term use is a different matter, and the evidence is still developing. A 2025 observational study on melatonin and heart failure – presented at the American Heart Association’s Scientific Sessions – found an association between melatonin use beyond one year and higher rates of heart failure diagnosis in people with chronic insomnia. That study was observational and non-peer-reviewed, meaning it cannot establish causation, and researchers were explicit that the people most likely to use melatonin long-term already carry elevated cardiac risk. But the finding reinforces what the 2026 pain review itself concluded: melatonin’s safety evidence currently extends to short-term use, and chronic use without physician oversight is not what the data supports. You can read more about that study in our earlier coverage of melatonin and heart failure risk.
Evidence Quality: Why This Isn’t a Green Light to Self-Medicate
Prior systematic reviews of melatonin’s analgesic effects have been criticized for reporting unreliable conclusions or including heterogeneous study designs – mixing randomized controlled trials with non-randomized studies – making it difficult to isolate melatonin’s actual effect on musculoskeletal pain. The 2026 review addressed this by restricting inclusion to RCTs only, which is methodologically stronger. But that restriction didn’t eliminate all concerns.
The certainty of evidence was rated low to moderate using GRADE (a standardized framework for assessing evidence quality in clinical research). Low-to-moderate certainty means the true effect could differ from what the pooled data show. Trials varied in how long they ran, how they measured pain, what populations they included, and what comparators they used. Some compared melatonin to placebo; others to active analgesics. The nine-point average reduction is a pooled result across that heterogeneous set – it should be read as a signal, not a prescription.
“We’re taking a medication we already understand and applying it to a problem that affects a huge proportion of the global population,” said co-author Professor Paulo Ferreira, Director of the Musculoskeletal Research Hub at the University of Sydney. That framing is appropriate – this is about applying existing knowledge more deliberately, not announcing a new wonder drug.
Read More: Struggling to Sleep? This Melatonin-Packed Late-Night Snack Could Be the Game-Changer
What to Do With This Information
The 2026 PAIN journal meta-analysis does not position melatonin as a standalone treatment for chronic musculoskeletal pain, and interpreting it that way would misread the evidence. What it does establish – with meaningful rigor, across 2,028 participants in 23 randomized trials – is that melatonin produces pain reductions in a range clinically similar to common analgesics, improves sleep quality in people with chronic pain, and does so with a side-effect profile comparable to placebo and no evidence of dependence.
For adults who are already using a sleep supplement for chronic pain alongside conditions like low back pain, osteoarthritis, or fibromyalgia, the evidence suggests they may be receiving more benefit than they realize. For those not yet using it, the data support raising the question with a physician – specifically asking whether a short-term trial (under three months, consistent with the safety evidence) at 3 mg at bedtime might be appropriate given their condition and current medication load.
Healthcare systems in 2024 and 2025 have been actively working to reduce opioid prescribing for chronic pain while maintaining management standards, with payers expanding support for physical therapy and minimally invasive alternatives. Melatonin, at its current evidence level, fits logically into that broader shift – not as a replacement for any therapy currently working, but as a low-cost, low-risk adjunct worth taking seriously. Clinicians managing patients with comorbid pain and sleep disruption, in particular, now have a more substantial evidence base to draw from when considering whether to add melatonin to the conversation.
The next step for the research is clear: larger trials with standardized dosing protocols, longer follow-up windows, and better controls for individual variation in melatonin metabolism. Until that data exists, the practical guidance is consistent: discuss it with your doctor, don’t exceed recommended short-term durations, and don’t stop any existing pain medication without medical supervision.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Millions Take Melatonin Every Night. Study Raises a Heart Concern.